Medicine, Health & Food

Medicine, Health & Food

Archive
Join as an Editor/Reviewer

Efficacy of antibodies, antivirals, and vaccination on SARS-CoV-2 Omicron Variant

Volume: 103  ,  Issue: 1 , June    Published Date: 21 June 2022
Publisher Name: IJRP
Views: 275  ,  Download: 214 , Pages: 395 - 406    
DOI: 10.47119/IJRP1001031620223448

Authors

# Author Name
1 Rudaina Ismail Osman Ahmed
2 Shahd S. Salah
3 Hassan I. Osman

Abstract

The Omicron variation (B.1.1.529) is a variation of SARS-CoV-2 (the infection that causes COVID-19) that was first answered to the World Health Organization (WHO) from South Africa on 24 November 2021. The omicron variation has transformations in both the RNA-subordinate RNA polymerase (RdRp) and the principle protease of SARS-CoV-2, which are focuses for antiviral medications like RdRp inhibitors (remdesivir and molnupiravir) and the primary protease inhibitor PF-07304814,5 which excites concern in regards to the diminished viability of these medications against omicron. WHO referred to it as "Variant of Concern". This is due to the 33 mutations this variant has and how it was believed to spread more rapidly than previous variants as the number of cases were increasing. The antibodies, vaccines, and anti-virals that were previously used were proven to be effective towards the previous variants, but with the surprising number of mutation, how effective will it be towards this variant? This is the scope and focus of this review article, to assess the efficacy towards it by collecting data. To our surprise, some of the well-known medications were found to be effective in some while in other studies proved otherwise. Omicron variant fortunately despite its rapid mode of spread is associated with speedy recoveries. This study states that previous medications will likely work on the Omicron variant although not as effectively as it does on previous variants, while a few maintain high efficacy rates.